ERBB2 and breast cancer: Through their work, they found that patients, who were defined by the 18-gene classifier as high risk, had significantly reduced rates of 5-year loco-regional recurrence, distant metastasis-free survival, and overall survival, regardless of lymph node status and breast cancer subtype based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2/neu status.